文献速递乳腺外科

预防性输卵管卵巢切除术与BRCA1/2乳腺癌切除术后生存

Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection.
PubMed 文献 · JAMA Surg · 2023-01-01

这项单中心回顾性队列研究纳入1972至2019年手术治疗的480例BRCA1/2乳腺癌患者,中位初始手术年龄40.0岁,评估预防性输卵管卵巢切除术(PSO)和预防性乳房切除术(PM)与预后的关联。PSO与死亡风险显著降低相关(HR 0.40,95%CI 0.25-0.64,P<.001),在BRCA1变异、三阴性病变和浸润性导管癌患者中更明显;初始或延迟PM与同侧乳腺肿瘤复发风险降低相关,但与总生存或乳腺癌特异性死亡无关。结论提示对接受根治性手术的BRCA1/2乳腺癌患者应提供PSO。

要点

  • PSO与BRCA1/2乳腺癌术后死亡风险显著降低相关(HR 0.40,95%CI 0.25-0.64,P<.001)。
  • BRCA1变异者PSO与死亡风险降低相关(HR 0.35,95%CI 0.20-0.63,P=.001)。
  • 初始或延迟PM与同侧乳腺肿瘤复发风险降低相关,但与总生存无关。

核心结论

  • 研究结果提示,对接受根治性手术的BRCA1/2乳腺癌患者应提供PSO以降低死亡风险,尤其BRCA1变异者应在乳腺手术时提供PSO。

研究设计与样本

  • 单中心三级转诊中心的回顾性队列研究,连续纳入1972至2019年手术治疗的浸润性乳腺癌患者,发现携带BRCA1或BRCA2变异后前瞻性随访,数据分析于2022年4月至2023年7月进行。
  • 共纳入480例患者,初始手术中位年龄40.0岁(IQR 34.0-46.0岁)。

主要发现

  • PSO与死亡风险显著降低相关(HR 0.40,95%CI 0.25-0.64,P<.001)。
  • BRCA1变异者PSO与死亡风险显著降低相关(HR 0.35,95%CI 0.20-0.63,P=.001)。
  • 三阴性病变者PSO与死亡风险显著降低相关(HR 0.21,95%CI 0.09-0.46,P=.002)。
  • 浸润性导管癌者PSO与死亡风险显著降低相关(HR 0.51,95%CI 0.31-0.84,P=.008)。
  • PSO与对侧乳腺癌或同侧乳腺肿瘤复发风险无显著关联;初始或延迟PM与同侧乳腺肿瘤复发风险降低相关,但与总生存或乳腺癌特异性死亡无显著关联。

临床怎么用

  • 作者认为,对接受根治性手术的BRCA1/2乳腺癌患者应提供PSO以降低死亡风险。
  • 作者认为,尤其应在乳腺手术时对BRCA1变异患者提供PSO。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Few studies have investigated whether prophylactic salpingo-oophorectomy (PSO) for patients with previously resected breast cancer who carry pathogenic germline BRCA1 or BRCA2 variants is associated with a reduced risk of cancer-specific death. OBJECTIVE: To assess the association of PSO and prophylactic mastectomy (PM) with prognosis after quadrantectomy or mastectomy as primary treatment for patients with BRCA1 or BRCA2 breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was performed in a single-institution, tertiary referral center. Consecutive patients with invasive breast cancer treated surgically between 1972 and 2019 were recruited and followed up prospectively after they were found to carry the BRCA1 or BRCA2 gene variant. The data analysis was performed between April 2022 and July 2023. EXPOSURE: Following breast surgery, some patients underwent PSO, PM, or both, whereas others did not. MAIN OUTCOMES AND MEASURES: The primary study end point was overall survival as measured by the Kaplan-Meier method. Secondary end points were crude cumulative incidence of breast cancer-specific mortality, ipsilateral breast tumor recurrence (IBTR), contralateral breast cancer, ovarian cancer, and ovarian cancer-specific mortality. RESULTS: Of 480 patients included in the cohort (median age at initial surgery, 40.0 years; IQR, 34.0-46.0 years), PSO was associated with a significantly reduced risk of death (hazard ratio [HR], 0.40; 95% CI, 0.25-0.64; P < .001). This reduction was most evident for patients carrying the BRCA1 variant (HR, 0.35; 95% CI, 0.20-0.63; P = .001), those with triple-negative disease (HR, 0.21; 95% CI, 0.09-0.46; P = .002), and those with invasive ductal carcinoma (HR, 0.51; 95% CI, 0.31-0.84; P = .008). Prophylactic salpingo-oophorectomy was not associated with risk of contralateral breast cancer or IBTR. Initial or delayed PM was associated with a reduced risk of IBTR but not with overall survival or breast cancer-specific mortality. CONCLUSIONS: The study findings suggest that PSO should be offered to all patients with BRCA1/2 breast cancer who undergo surgery with curative intent to reduce risk of death. In particular, PSO should be offered to patients with the BRCA1 variant at the time of breast surgery.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Martelli G, Barretta F, Vernieri C, et al. Prophylactic Salpingo-Oophorectomy and Survival After BRCA1/2 Breast Cancer Resection. JAMA Surg. 2023. PMID: 37792368. doi:10.1001/jamasurg.2023.4770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。